BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11825008)

  • 1. Empirical monotherapy with meropenem in serious bacterial infections in children.
    Hsu HL; Lu CY; Tseng HY; Lee PI; Lai HP; Lin WC; Hsieh YC; Lee CY; Huang LM
    J Microbiol Immunol Infect; 2001 Dec; 34(4):275-80. PubMed ID: 11825008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
    Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
    Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
    Kuo BI; Fung CP; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbapenems in paediatrics.
    Blumer JL
    Scand J Infect Dis Suppl; 1995; 96():38-44. PubMed ID: 7652502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections.
    Mohr JF
    Clin Infect Dis; 2008 Sep; 47 Suppl 1():S41-51. PubMed ID: 18713049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group.
    Mouton YJ; Beuscart C
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():145-56. PubMed ID: 8543490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
    Colardyn F; Faulkner KL
    J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections.
    Hou F; Li J; Wu G; Zheng B; Chen Y; Gu J; Wang H; Huo L; Xue X; Jia C; Yin Y; Tian X; Ren S
    Chin Med J (Engl); 2002 Dec; 115(12):1849-54. PubMed ID: 12622937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meropenem compared with ceftazidime in the empiric treatment of acute severe infections in hospitalized children. Italian Pediatric Meropenem Study Group.
    Principi N; Marchisio P
    J Chemother; 1998 Apr; 10(2):108-13. PubMed ID: 9603635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of effectiveness and safety of generic formulation of meropenem for treatment of infections at Siriraj Hospital.
    Angkasekwinai N; Werarak P; Chaiyasoot K; Thamlikitkul V
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S217-24. PubMed ID: 21721450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors.
    Oguz A; Karadeniz C; Citak EC; Cil V; Eldes N
    Pediatr Hematol Oncol; 2006; 23(3):245-53. PubMed ID: 16517540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of meropenem as an empirical treatment for febrile neutropenia in children with cancer.
    Pancharoen C; Mekmullica J; Buranachonapa J; Trongjit D; Nuchprayoon I; Vanichsetakul P; Seksarn P; Thisyakorn U
    J Med Assoc Thai; 2003 Jun; 86 Suppl 2():S174-8. PubMed ID: 12929986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the efficacy and safety of isepamicin in the treatment of various bacterial infections.
    Petrikkos G; Giamarellou H; Tsagaraki C; Pefanis A
    J Chemother; 1995 Jun; 7 Suppl 2():161-4. PubMed ID: 8622106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meropenem in the treatment of febrile neutropenic children.
    Müller J; Garami M; Constantin T; Schmidt M; Fekete G; Kovács G
    Pediatr Hematol Oncol; 2005 Jun; 22(4):277-84. PubMed ID: 16020114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of aztreonam in the treatment of serious gram-negative bacterial infections.
    LeFrock JL; Smith BR; Chandrasekar P; Rolston KV; Molavi A; Kannangara W
    Arch Intern Med; 1987 Feb; 147(2):325-8. PubMed ID: 3813751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meropenem.
    Shah D; Narang M
    Indian Pediatr; 2005 May; 42(5):443-50. PubMed ID: 15923690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meropenem use and colonization by antibiotic-resistant Gram-negative bacilli in a pediatric intensive care unit.
    Toltzis P; Dul M; O'Riordan MA; Melnick D; Lo M; Blumer J
    Pediatr Crit Care Med; 2009 Jan; 10(1):49-54. PubMed ID: 19057450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical pharmacology and indications of meropenem in severe pediatric infection].
    Honorato J; Sádaba B; Díaz M
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():38-44. PubMed ID: 9410068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infection.
    Arguedas A; Cespedes J; Botet FA; Blumer J; Yogev R; Gesser R; Wang J; West J; Snyder T; Wimmer W;
    Int J Antimicrob Agents; 2009 Feb; 33(2):163-7. PubMed ID: 18945594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ceftazidime in common infections in childhood. Experience in 262 cases].
    Fanos V; Fostini R; Panebianco R; Danieli D
    Clin Ter; 1991 Jun; 137(5):327-32. PubMed ID: 1832605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.